Is GPR68 a potential master switch for fibrotic and inflammatory diseases?
Simona E Carbone, Michelle P Papadimitriou and Darren J Kelly, discuss why GPR68 has been considered an attractive target for cancer therapy – albeit difficult to drug – and highlight its exciting potential in the development of drugs to treat a range of inflammatory and fibrotic diseases.
GPR68, or OGR1, is an orphan, acid-sensing G-protein coupled receptor (GPCR). It is expressed widely throughout the body and is silent in healthy tissue. GPR68 is activated following injury or disease when there is an increase in acidity in the extracellular environment and has dual functionality as a mechanosensor activated by shear force. It serves as a surveillance mechanism, detecting acidosis that can occur due to changes in tissue metabolism and cellular stress. GPR68 regulates cellular functions in response to acidosis that result in further inflammation and fibrosis1. This means that GPR68 has a role in how acidosis can promote ongoing inflammation in various diseases – acting as potential master switch in disease progression.
GPR68 and its role in cancer
The cancer field has been historically one of the most active spaces in the investigation of the role of GPR68 in disease progression and the therapeutic advantages of targeting this receptor2. An acidic tissue environment is a key feature of many pathophysiological conditions and a hallmark of cancers in general where the extracellular tumour microenvironment can range in pH from 5.5-7.0, much lower than healthy tissue which is around 7.4. Acid-base levels are disrupted in tumours for various reasons including poor vascularisation, tissue hypoxia and altered cell metabolism. Emerging evidence indicates that tissue acidity is not simply a passive effect of tumour growth. It is also a key regulator of tumour biology, including tumorigenesis and metastasis and the potential of targeting tissue acidity to reduce tumour growth is being investigated. Targeting the acidity surveillance system, GPR68, may be one avenue to achieve this.
GPR68 expression has been found in various human cancers (cell lines and solid-state tumours) including chronic lymphocytic leukaemia cells, colon and breast cancer cells, pancreatic ductal adenocarcinoma cells and tumours. The broad applicability of targeting acidosis for many cancers and the expression of the receptor in a range of cell types and tumours makes GPR68 a very attractive target. This has seen Cumulus Oncology collaborate with leadXpro AG to direct their efforts towards successfully solving a high-resolution structure of GPR68 from which novel small molecules are being designed.
GPR68 is expressed not only by tumour cells themselves, but also in numerous immune cells, particularly cancer associated fibroblasts, macrophages, and T cells. While this is an additional avenue for investigation in terms of tumour biology, it also provides novel implications in the development of therapeutics for inflammation and fibrosis.
Inflammation and GPR68
Acidosis is a key feature of chronic inflammation in conditions such as rheumatoid arthritis and inflammatory bowel disease. A driving factor for this acidic environment is the increased metabolic requirements for infiltrating immune cells to the areas of inflammation. The acidic environment then promotes further inflammation through a number of mechanisms including modulating further release of cytokines and metabolites and changing the differentiation state of immune cells. Additional contributors to the acidic environment include hypoxia resulting from vascular changes, oedema formation and increasing metabolic demands of the tissue.
Many current therapies and those in development aim to limit inflammation by targeting immune cells or the actions of the cytokines they release. This approach will not necessarily restore the physiological pH of tissues, which is an additional driver of inflammation. However, modulating the cellular response to pH will change the inflammatory state in tissues. For this reason, targeting GPR68 presents a promising approach for the treatment of inflammatory conditions. Inflamed colon tissue from patients with inflammatory bowel disease (IBD) has increased GPR68 expression compared to non-inflamed tissue, and tissue from non-IBD patients. Increasing GPR68 expression also correlates with IBD patient clinical scores. In inflamed tissues, cells that have key roles in inflammation such as macrophages, granulocytes, endothelial cells, and fibroblasts all express GRP683.

GPR68 in fibrosis
Wound healing and repair are important aspects in the recovery from inflammation. However, in a bid to quickly limit the implications of inflammation, excessive wound healing can result. Fibrosis describes when this wound healing process becomes pathological, and connective tissue replaces normal parenchymal tissue. As the process continues unchecked, this leads to considerable tissue remodeling and deposition of connective tissue. The result is interference or complete inhibition and loss of function of the organ affected. There are no approved drugs which effectively inhibit progression of tissue fibrosis for any chronic systemic disease.
Fibrosis contributes to many serious and life-limiting fibrotic diseases, including IBD, Chronic Kidney Disease (CKD), Systemic Sclerosis (SSc), Focal Segmental Glomerulosclerosis (FSGS) and others. When GPR68 is activated by acidosis during tissue injury it stimulates several intracellular pathways that contribute to fibrosis and inflammation including promoting collagen deposition, extracellular matrix remodelling and vascular remodelling, and modulating the release of immune and non-immune cytokines (e.g. IL-6, IL-8, TNF and TGFb). These broad-ranging actions on multiple fibrotic and inflammatory pathways make GPR68 a master regulator of fibrosis. In addition, given tissue remodelling and stiffness is part of fibrosis, the mechanosensory activation of GPR68 may also play a role. Therefore, inhibiting GPR68 will likely have clinical benefit for many fibrotic conditions.
Asengeprast (FT-011) is a GPR68 inhibitor currently in clinical development for the treatment of SSc. Key cells in fibrosis, fibroblasts and NK cells, have increased GPR68 expression when sourced from SSc patient biopsies versus controls. Treating SSc patient fibroblasts in vitro with asengeprast reduced protein expression of key fibrotic markers and collagen gel contraction mediated by the inflammatory cytokine, TGFb. In a phase IIa clinical trial the benefit of asengeprast for the treatment of SSc was tested4. Results from the study showed 60% of the participants treated with asengeprast had improvement in clinically important measures of disease severity and organ damage (as measured by American College of Rheumatology Composite Response Index in Systemic Sclerosis – ACR-CRISS), compared to only 10% of those who received the placebo. Additional improvements were observed in lung function, overall health, and the ability to carry out daily activities. Coinciding with this clinical benefit, in skin biopsies from participants receiving asengeprast, downregulation of fibrotic genes and pathways was measured. These results highlight the therapeutic opportunity of inhibiting GPR68 for the treatment of other fibrotic and inflammatory conditions. Further GPR68 inhibitors are also under development with a second compound entering a phase II trial for chronic kidney disease.
The future of GPR68 as a master switch
Despite the attractiveness of GPR68 as a therapeutic target across a range of indications it has traditionally been difficult to drug, partly due to the lack of crystal structure of the receptor, and because it is an orphan receptor. Until recently few selective compounds have been identified as GPR68 agonists or modulators.
We believe asengeprast and Certa Therapeutics’ portfolio of GPR68 inhibitors to be the only antagonists in clinical development. However, as detailed above, an acidic tissue environment is a hallmark of tumour biology, inflammation and fibrosis meaning GPR68 targeting compounds have broad therapeutic potential across a range of diseases. The role of the receptor to survey the acidic environment and switch the tissue state to a pro-inflammatory and pro-fibrotic condition makes it a master regulator of disease progression. Having pioneered the field of GPR68 modulation for the treatment of inflammation and fibrosis, a number of drug candidates are now in late-stage clinical testing at Certa Therapeutics. The increasing presence of other companies with programs targeting the receptor, including Cumulus Oncology and Proton Bio, heralds the growing excitement around this novel target.
From DDW Volume 26 – Issue 1, Winter 2024/25 Read the digital issue
References
- Imenez Silva PH, Wagner CA. Pflugers Arch. 2022;474(5):487-504. https://doi.org/10.1007/s00424-022-02671-1
- Insel PA et al Future Medicinal Chemistry. 2020 Mar;12(6):523-532. doi: 10.4155/fmc-2019-0357
- de Vallière C, et al. Int. J. Mol. Sci. 2022, 23, 1419. https://doi.org/10.3390/ijms23031419
- Nikolopoulos D et al. 2024. Annals of the Rheumatic Diseases 83(Suppl 1):49-49 83. https://doi.org/10.1136/ard-2024-225664
About the authors:
Dr Simona Carbone is Program Manager at Certa Therapeutics. She has more than 15 years of experience in biomedical research in the field of neurogastroenternology. Carbone holds a concurrent role as Senior Research Fellow at Monash University (Monash Institute of Pharmaceutical Sciences), where she leads an industry-facing research laboratory. Simona’s research laboratory receives funding from industry, government, and philanthropic sources.
Dr Michelle Papadimitriou is Research and Development Director at Certa Therapeutics. She has more than 15 years of experience in biomedical research with more than five years of experience in drug development, managing pre-clinical efficacy, safety and toxicology studies to progress drug candidates to Phase I and Phase II clinical trials.
Professor Darren Kelly is a scientist who led a team that developed a series of small molecule inhibitors of GPR68 with the aim of tackling fibrotic diseases upstream of other targeted biological pathways. He is currently CEO and Managing Director of Certa Therapeutics a company with a consolidated portfolio of specific molecules which all target GPR68.
